Lithium and synaptic plasticity

Bipolar Disorders

Volumn 1, Issue 2, 1999, Pages 87-90

  Salinas, Patricia C ^a   Hall, Anita C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Axonal remodelling; Bipolar disorder; GSK 3 ; Inositol; Lithium; PKC; Synaptic proteins

Indexed keywords

GLYCOGEN SYNTHASE KINASE; GLYCOGEN SYNTHASE KINASE 3; INOSITOL; LITHIUM DERIVATIVE; NEUROMODULIN; PROTEIN KINASE (CALCIUM,CALMODULIN); PROTEIN KINASE C; TRANQUILIZER;

BIPOLAR DISORDER; BRAIN LEVEL; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; NERVE CELL PLASTICITY; PATHOPHYSIOLOGY; REVIEW;

ANTIMANIC AGENTS; BIPOLAR DISORDER; BRAIN CHEMISTRY; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; GAP-43 PROTEIN; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASES; HUMANS; INOSITOL; LITHIUM COMPOUNDS; NEURONAL PLASTICITY; PROTEIN KINASE C;

EID: 0033301406     PISSN: 13985647     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-5618.1999.010205.x     Document Type: Short Survey

References (36)

1. Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1989; 59: 411-419.
2. Lubrich B, Patishi Y, Kofman O, Agam G, Berger M, Belmaker RH. Lithium-induced inositol depletion in rat brain after chronic treatment is restricted to the hypothalamus. Mol Psychiatry 1997; 2: 407-412.
3. + increases accumulation of inositol 1,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate in cholinergically stimulated brain cortex slices in guinea pig, mouse and rat. The increases require inositol supplementation in mouse and rat but not in guinea pig. Biochem J 1992; 282: 377-385.
4. Dixon JF, Lee CH, Los GV, Hokin LE. Lithium enhances accumulation of [3H]inositol radioactivity and mass of second messenger inositol 1,4,5-trisphosphate in monkey cerebral cortex slices. J Neurochem 1992; 59: 2332-2335.
5. Dixon JF, Los GV, Hokin LE. Lithium stimulates glutamate "release" and inositol 1,4,5-trisphosphate accumulation via activation of the N-methyl-D-aspartate receptor in monkey and mouse cerebral cortex slices. Proc Natl Acad Sci USA 1994; 91: 8358-8362.
6. Williams MB, Jope RS. Modulation by inositol of cholinergic-and serotonergic-induced seizures in lithium-treated rats. Brain Res 1995; 685: 169-178.
7. Spector R. Myo-inositol transport through the blood-brain barrier. Neurochem Res 1988; 13: 785-787.
8. Belmaker RH, Revazov A, Bersudskey Y, Kofman O. Inositol passes the blood-brain barrier sufficiently to reverse lithium effects on behaviour in rats. Clinical Neuropharmacol 1992; 15: 606A-607A.
9. Dixon JF, Hokin LE. The antibipolar drug valproate mimics lithium in stimulating glutamate release and inositol 1,4,5-trisphosphate accumulation in brain cortex slices but not accumulation of inositol monophosphates and bisphosphates. Proc Natl Acad Sci USA 1997; 94: 4757-4760.
10. Price LH, Heninger GR. Lithium in the treatment of mood disorders [see comments]. N Engl J Med 1994; 331: 591-598.
11. Evans MS, Zorumski CF, Clifford DB. Lithium enhances neuronal muscarinic excitation by presynaptic facilitation. Neuroscience 1990; 38: 457-468.
12. Motohashi N. GABA receptor alterations after chronic lithium administration. Comparison with carbamazepine and sodium valproate. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16: 571-579.
13. Dixon JF, Hokin LE. Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex. Proc Natl Acad Sci USA 1998; 95: 8363-8368.
14. Ramakers GM, Pasinelli P, Hens JJ, Gispen WH, De Graan PN. Protein kinase C in synaptic plasticity: changes in the in situ phosphorylation state of identified pre-and postsynaptic substrates. Prog Neuropsychopharmacol Biol Psychiatry 1997; 21: 455-486.
15. Manji HK, Potter WZ, Lenox RH. Signal transduction pathways. Molecular targets for lithium's actions. Arch Gen Psychiatry 1995; 52: 531-543.
16. Pasinelli P, Ramakers GM, Urban IJ, Hens JJ, Oestreicher AB, de Graan PN. Long-term potentiation and synaptic protein phosphorylation. Behav Brain Res 1995; 66: 53-59.
17. Benowitz LI, Routtenberg A. GAP-43: an intrinsic determinant of neuronal development and plasticity. Trends Neurosci 1997; 20: 84-91.
18. Dekker LV, De Graan PNE, Oestreicher AB, Vesteeg DHG, Gispen WH. Inhibition of noradrenaline release by antibodies to B-50 (GAP-43). Nature 1989; 342: 74-76.
19. Lucas FR, Salinas PC. WNT-7a induces axonal remodelinc and increases synapsin I levels in cerebellar neurons. Dev Biol 1997; 192: 31-44.
20. Robinson PJ. The role of protein kinase C and its neuronal substrates dephosphin, B-50, and MARCKS in neurotransmitter release. Mol Neurobiol 1991; 5: 87-130.
21. Watson DG, Lenox RH. Chronic lithium-induced down-regulation of MARCKS in immortalized hippocampal cells: potentiation by muscarinic receptor activation. J Neurochem 1996; 67: 767-777.
22. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93: 8455-8459.
23. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/Factor A. EMBO J 1990; 9: 2431-2438.
24. Takahashi M, Tomizawa K, Kato R, Sato K, Uchida T, Fujita SC. Localization and developmental changes of tau protein kinase I/glycogen synthase kinase-3beta in rat brain. J Neurochem 1994; 63: 245-255.
25. Insall R. Glycogen synthase kinase and Dictyostelium development: old pathways pointing in new directions? Trends Genet 1995; 11: 37-39.
26. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Develop 1997; 11: 3286-3305.
27. Lucas FR, Goold RG, Gordon-Weeks PR, Salinas PC. Inhibition of GSK-3beta leading to the loss of phosphorylated MAP-IB is an early event in axonal remodelling induced by WNT-7a or lithium. J Cell Sci 1998; 111: 1351-1361.
28. Sanchez Martin C, Diaz-Nido J, Avila J. Regulation of a site-specific phosphorylation of the microtubule-associated protein 2 during the development of cultured neurons. Neuroscience 1998; 87: 861-870.
29. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics Wingless signalling in intact cells. Curr Biol 1996; 6: 1664-1668.
30. Freeman MP, Stoll AL. Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry 1998; 155: 12-21.
31. Watson DG, Watterson JM, Lenox RH. Sodium valproate down-regulates the myristoylated alanine-rich C kinase substrate (MARCKS) in immortalized hippocampal cells: a property of protein kinase C-mediated mood stabilizers. J Pharmacol Exp Ther 1998; 285: 307-316.
32. Petty F. GABA and mood disorders: a brief review and hypothesis. J Affect Disord 1995; 34: 275-281.
33. Vadnal R, Parthasarathy R. Myo-inositol monophosphatase: diverse effects of lithium, carbamazepine, and valproate. Neuropsychopharmacology 1995; 12: 277-285.
34. Cheng G, Huang LD, Yiang YM, Manji H. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 1999; 72: 1327-1330.
35. Wagner U, Brownlees J, Irving NG, Lucas FR, Salinas PC, Miller CCJ. Overexpression of the mouse dishevelled-1 protein inhibits GSK-3 beta-mediated phosphorylation of tau in transfected mammalian cells. Febs Lett 1997; 411: 369-372.
36. Lijam N, Paylor R, McDonald MP, Crawley JN, Deng CX, Herrup K. Social interaction and sensorimotor gating abnormalities in mice lacking Dv11. Cell 1997; 90: 895-905.